FENIX PHARMA È BEST WORKPLACES™ ITALIA 2025

/in /by

Fenix pharma dopo essere rientrata nella classifica dei Great Place to work sia nel 2024 che nel 2025  e’ rientrata fra le Best Work place 2025, fra tutte le aziende di tutti i settori classificandosi al 13° posto nella categoria 50-149 dipendenti.

“Fin dalle origini la centralità delle persone ha rappresentato un must per Fenix pharma e tutte le strategie si sono basate su questo. Questo riconoscimento evidenzia l’impegno continuo dell’azienda nel costruire un ambiente lavorativo altamente qualificato, motivante e orientato al benessere e alla crescita professionale dei propri collaboratori”  ha dichiarato l’AD S.Manfredi 

Secondo l’indagine condotta da Great Place to Work® Italia, le aziende premiate nel 2025 hanno ottenuto una media del Trust Index dell’84%, un indicatore che riflette l’alto livello di fiducia e soddisfazione tra i dipendenti. Fenix Pharma emerge come esempio di best practice nell’ambito della promozione di una cultura aziendale positiva, inclusiva e volta al miglioramento continuo delle relazioni interne.

“Fenix Pharma ha sempre sostenuto che il successo aziendale sia strettamente legato al benessere delle persone. Per questo motivo, ha messo in atto strategie mirate a favorire la crescita professionale dei propri collaboratori, incentivando un forte senso di appartenenza e impegno all’interno del team. L’azienda ha inoltre posto un particolare focus sul miglioramento delle condizioni di lavoro, con l’obiettivo di garantire un ambiente altamente motivante e produttivo, in linea con le best practice del settore farmaceutico”

Secondo il Responsabile HR G. Paolucci

 “Questo riconoscimento non rappresenta solo un traguardo per Fenix Pharma, ma anche un forte stimolo a proseguire nel proprio percorso di eccellenza. 

L’azienda continuerà a investire nelle proprie risorse umane, riconoscendo il valore fondamentale delle persone come motore della propria crescita. Ringraziamo chi ha creduto in noi, chi ci sostiene oggi e chi ci sosterrà domani. Il nostro viaggio continua!”

 Ulteriori informazioni ai seguenti links:

https://www.ilsole24ore.com/art/le-migliori-aziende-doppiano-media-italiana-fiducia-e-crescita-AGhusPTD

https://tg24.sky.it/economia/2025/03/22/migliori-ambienti-lavoro-italia-classifica

FENIX PHARMA DEBUTS AS EXHIBITOR AT ARAB HEALTH IN DUBAI

/in /by

A new significant milestone for Fenix Pharma, as it will participate for the first time as an exhibitor at Arab Health in Dubai, the largest international trade fair dedicated to the healthcare and pharmaceutical sectors, where the biggest players in the pharmaceutical industry come together to shape the future of healthcare.

Building on its strong presence in Europe, Fenix Pharma aims to expand its reach in global markets, thanks to a portfolio of medical devices, dietary supplements and a line of atented products supported by clinical studies. Additionally, our offering includes a complete and advanced range of skincare products, designed to meet the needs of an increasingly demanding clientele.

"Arab Health is a unique opportunity to showcase our products to a global audience and to establish new strategic collaborations. We are excited to present solutions that combine quality, innovation, and a patient-centered approach," said Salvatore Manfredi, CEO of Fenix Pharma.

This debut in Dubai marks a new chapter in the history of Fenix Pharma, demonstrating how a vision based on quality and determination can lead to extraordinary results.

Fenix Pharma promotes the technological transition - Digitalization Voucher for SMEs – Regional FESR Lazio Program 2021-2027

/in /by

Fenix Pharma participated in the SME DIGITALIZATION VOUCHER – Regional FESR Lazio Program 2021-2027, being awarded a credit of €100,000.

By utilizing the Digital Diagnosis of an independent Innovation Manager, it effectively identified the investments and interventions to be made in order to promote a technological transition and consequently improve business processes. 

Through the acquisition of new digital technologies, it will be possible to support the sales network, reduce costs and operational risks, resulting in increased competitiveness in the sector. 

Digital Technologies: 

Digital Workplace  

Purchase of digital workstations to streamline communication between processes and increase productivity. 

Digital Commerce & Engagement 

Expansion of digital channels to enhance customer loyalty activities. 

Cloud Computing 

Transfer data or apps from local servers to cloud infrastructure to modernize the IT structure and reduce management costs. 

Cyber Security 

Ensure the security and protection of IT resources. 

WAVE PHARMA in support of women with breast cancer in Nepal

/in /by

Breast Cancer: Roy De Vita in Nepal for the 10.19 Project in collaboration with 'Ripartiamo'

The 10.19 project for the fight against breast cancer, born from an idea by Roy De Vita in collaboration with Ripartiamo Aps, is now in full swing. The renowned oncoplastic surgeon, Head of the Plastic Surgery Division at the "Regina Elena" National Cancer Institute in Rome, has departed for Nepal with volunteers from the association, which is active in Italy and worldwide, for a humanitarian mission aimed at training local medical personnel involved in breast cancer prevention and treatment. The project, divided into three phases, saw the start of the second phase on September 24, and will conclude on Saturday, September 30. At the foot of the Himalayas, Prof. De Vita will hold training sessions with healthcare personnel, involving surgeons and nurses in study and sharing days focused on early diagnosis methods to promptly treat breast cancer, with the aim of reducing mortality rates among women, both young and older, in the Nepalese population.

The project, which became active this week, started last July when Prof. De Vita made an initial trip to Nepal to identify the most in-need population and gather the concerns of women affected by breast cancer, as well as the medical staff from hospitals in Kathmandu and other areas of the Asian country, farther from the capital, in order to understand their real needs.
In questi due mesi, il prof. De Vita ha messo a punto la sua missione umanitaria e, supportato dalla sua equipe del Regina Elena, è tornato in Nepal insieme al suo Aiuto, il dott. Marcello Pozzi, dove, presso l’ospedale di Birthamode, terrà la formazione per le equipe mediche locali inerenti le tecniche più avanzate per l’asportazione dei tumori mammari e la ricostruzione del seno post mastectomia e coordinerà lo screening clinico.
Tra i templi induisti e i luoghi di culto buddisti, infatti vicino all’ospedale Purbanchal si terrà lo screening delle pazienti. Sarà l’occasione per molte donne di accedere a sistemi di prevenzione e di cura efficaci che possono ridonare speranza e garanzia per una migliore qualità della vita.

“Il nome del progetto 10.19 l’ho scelto – spiega il professor De Vita – perché è la Giornata internazionale contro il cancro al seno. Per noi è importante diffondere la cultura della sorveglianza – parola che preferisco a quella di “prevenzione” – e formare il personale medico in modo che possa dare un contributo sempre più efficace alla lotta al tumore al seno che nel mondo è il più frequente tumore femminile”
Il progetto 10.19 è sostenuto da Ripartiamo Aps, che supporta le comunità più disagiate e si dedica a missioni umanitarie in Italia e all’estero, alla raccolta di medicinali e alla consegna di pacchi viveri. Per prima volta, l’associazione è impegnata in un progetto di sanità pura come quello della chirurgia oncoplastica del tumore al seno.
Sponsor del progetto sono Wave Pharma, del gruppo Fenix Pharma, azienda specializzata nella distribuzione di farmaci per l’oncologia, e Sielte, società leader nel settore delle telecomunicazioni e dei servizi digitali.

Hericium erinaceus, in combination with natural flavonoids/alkaloids and vitamins B3/B8, may improve the inflammatory state in the tissues of inflammatory bowel diseases: an ex vivo study

/in /by

Antonietta Gerarda Gravina1*†, Raaele Pellegrino1†, Giovanna Palladino1, Annachiara Coppola1, Giovanni Brandimarte2, Concetta Tuccillo3, Fortunato Ciardiello3, Marco Romano1 and Alessandro Federico1

1Hepatogastroenterology Unit, Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy, 2Division of Internal Medicine and Gastroenterology, Cristo Re Hospital, Rome, Italy, 3Medical Oncology Unit, Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy

**Hericium erinaceus, berberine, and quercetin have been shown to be effective in experimental colitis. Their effects in inflammatory bowel diseases (IBD) in humans are not yet known. This ex vivo study aims to evaluate the anti-inflammatory potential of a nutraceutical containing HBQ-Complex® (H. erinaceus, berberine, and quercetin), biotin, and niacin in patients with inflammatory bowel disease.** **Tissue samples were obtained from the Apparently Normal Mucosa (NAM) or Inflamed Mucosa (IM) of 20 patients with IBD. The expression of mRNA and proteins COX-2, IL-10, and TNF-α was determined in biopsies of NAM and IM (T0). The IM samples were incubated with HBQ-Complex® (with the addition of niacin and biotin), and the levels of COX-2, IL-10, and TNF-α were assessed at 120 minutes (T1) and 180 minutes (T2).** **Incubation with this compound resulted in a progressive reduction in the expression of COX-2 and TNF-α at T1/T2 in the IM. IL-10 showed an opposite trend, with a progressive increase in expression during the same time window. HBQ-Complex® (with the addition of niacin and biotin) reduces the expression of pro-inflammatory cytokines in IBD tissues. Conversely, it leads to a progressive increase in the expression of the anti-inflammatory cytokine IL-10.**

Bibliography

Antonietta Gerarda Gravina et al. Hericium erinaceus, in combination with natural flavonoid/alkaloid and B3/B8 vitamins, can improve inflammatory burden in Inflammatory bowel diseases tissue: an ex vivo study. Front Immunol. 2023; 14: 1215329.

Fenix Pharma acquires Wave Pharma: new opportunities in oncology.

/in /by

Fenix is the first pharmaceutical cooperative in Italy: revenue and objectives on the rise.

**Fenix Pharma, through its subsidiary Fenix Life, announces the acquisition of Wave Pharma, a pharmaceutical company focused on oncology. Wave owns and promotes drugs for the treatment of breast cancer in postmenopausal women.** "Eleven years after the founding of Fenix Pharma," comments CEO Salvatore Manfredi, "we are excited to embark on a growth journey by completing the acquisition of Wave and welcoming their team of professionals to Fenix. This acquisition will allow us to enter a field where we believe our approach, based on cooperative values and principles, can contribute to supporting the medical community in managing cancer patients and the therapies they require. We will strengthen our presence in the field and our commitment to providing the oncology treatments patients need." Thanks to this new step, Fenix Pharma continues its growth strategies in specialized therapeutic areas and consolidates a total network of 100 people, including 91 medical sales representatives and 9 Area Managers.

**The story of Fenix Pharma begins in the summer of 2011, when the pharmaceutical multinational Warner Chilcott suddenly decided to exit the European market, effectively shutting down the company and, most importantly, leaving its employees without jobs.** In the same year, from the ashes of that closure, thanks to the foresight of some of those employees, Fenix Pharma was born with the goal of uniting forces to pursue a shared project of life and work. Over the course of more than eleven years, Fenix Pharma has grown and successfully established itself in the pharmaceutical market, driven by the innovative strength of its products and the cooperative spirit of the people who joined the project. Today, Fenix Pharma represents the first and only pharmaceutical cooperative in Italy, with a sales force of about one hundred people. Fenix Pharma operates in the distribution of pharmaceuticals, medical devices, and dietary supplements, across various therapeutic areas (**gastroenterology, osteoarticular, otorhinolaryngology, urogynecology**), distinguishing itself for its high-quality product standards and its commitment to protecting the buyer. These values have enabled Fenix Pharma to achieve significant results year after year, looking to the future with hope and enthusiasm. As evidenced by the results: thanks to the adoption of a hybrid business model that includes both the development of proprietary products and products promoted on behalf of a long-term partner, the company has experienced consistent growth, reaching a turnover of over 10 million euros.

**The acquisition of Wave Pharma is part of the milestones the company has set for itself, including the increase of pharmaceutical properties and the expansion of its offering of dietary supplements and medical devices, with the goal of launching at least two products per year in each therapeutic area.**

https://www.dottnet.it/articolo/32532459/i-fenix-pharma-acquisisce-wave-pharma-nuovi-sbocchi-verso-l-oncologia-i-/

Fenix Pharma present at the IX edition of the National GCORL Congress.

/in /by

From November 16 to 19, Fenix Pharma will be present at the 9th edition of the GCORL National Congress (Campania ENT Group) at the Grand Hotel Salerno, in Salerno.

This edition of the Congress aims to provide educational guidance through multiple and multidisciplinary sessions, outlining the proper training path to become "a skilled and up-to-date ENT specialist," in line with current advancements in the treatment of medical and surgical conditions in the ENT field.

At our booth, Federico Lauritano and Daniele Laurini will be discussing our latest innovation, **Otizon**, an innovative otological solution based on ozonized oil in liposomes, designed for the management of external ear diseases.

Effectiveness of a nutraceutical based on alpha-lipoic acid, acetyl L-carnitine, and B vitamin complex in the treatment of craniofacial neuralgias and tinnitus.

/in /by

 

Craniofacial Neuralgias

Premise:
The treatment of craniofacial neuralgias represents an area of dissatisfaction for specialists due to the complex understanding of the pathophysiology of neuropathic pain. Recent evidence has shown that oxidative stress plays a crucial role in the pathogenesis of neuralgias. Therefore, nutraceuticals formulated with antioxidant compounds have been proposed as potential treatments. To analyze current treatments for craniofacial neuropathic pain and assess their effectiveness, a national survey was conducted, involving 33 ENT centers across Italy and 264 patients.

Result
The survey revealed that craniofacial neuralgias negatively impact patients' quality of life (QoL), causing sleep disturbances, reduced work performance, and difficulty maintaining regular meals. Patients treated with dietary supplements containing alpha-lipoic acid, acetyl-L-carnitine, and a vitamin B complex (Tioneural retard), which act synergistically on inflammation of the peripheral nervous system, showed a reduction in the VAS score attributed to neuralgic discomfort. After 3 months of treatment with Tioneural retard, patients reported a statistically significant reduction in neuralgic pain measured with the VAS scale (-62.3%).

Conclusion
 Antioxidant compounds, due to their neuroprotective effects, are effective in reducing neuropathic pain. The reduction of oxidative stress can therefore be considered a promising approach in the treatment of neuropathic pain and offers hope to patients who are currently forced to live with chronic pain, which is often disabling.

Tinnitus

Premise:
Tinnitus affects more than 10% of the population, representing a significant social and economic burden. Although several hypotheses have been proposed to explain the development of tinnitus, its etiology remains unclear, hindering the development of effective therapies. Recent evidence has shown that oxidative stress plays a crucial role in the pathogenesis of tinnitus, leading to growing interest in the role of nutraceuticals as a potential therapeutic approach. To analyze tinnitus management strategies and assess their effectiveness, a national survey was conducted involving 33 otolaryngologists across the country and 306 patients.

Result
The results showed that tinnitus is not yet fully recognized as a condition in its own right, which leads to it not being adequately treated. Among the treatments, dietary supplements containing alpha-lipoic acid, acetyl L-carnitine, and B-vitamin complex (Tioneural retard) have proven effective in reducing the discomfort caused by tinnitus. Patients treated with Tioneural retard showed a 37% reduction in tinnitus-induced discomfort, as measured by the VAS score, after three months.

Conclusion
The growing focus on oxidative stress as a cause of tinnitus and as a potential therapeutic target represents a promising indication for the use of nutraceuticals with antioxidant activity in the treatment of this condition.

Bibliography

  • M. Gelardi et al. The effectiveness of dietary supplements based on alpha-lipoic acid, acetyl l-carnitine and vitamin B complex in the treatment of craniofacial neuralgia. JOURNAL OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS. Vol. 36, no. 1 (S2), 15-23 (2022)
  • M. Gelardi et al. The effect of dietary supplements-based alpha-lipoic acid, acetyl l-carnitine and vitamin B complex in patients with tinnitus. JOURNAL OF BIOLOGICAL REGULATORS & HOMEOSTATIC AGENTS. Vol. 36, no. 1 (S2), 25-33 (2022)

Performance of a nutraceutical with a multi-component formulation in patients with symptomatic uncomplicated diverticular disease (SUDD).

/in /by

Fenix Pharma presented at the FISMAD congress, held in Rome from May 11 to 14, 2022, the significant results achieved with ENTEROFLEGIN in patients with symptomatic uncomplicated diverticular disease (SUDD). These findings were published in the study “Performance of a multicompound nutraceutical formulation in patients with symptomatic uncomplicated diverticular disease” (Brandimarte et al., 2022, Minerva Medica).

ENTEROFLEGIN, developed through Fenix Pharma's research, is an innovative nutraceutical with PREBIOTIC and ANTI-INFLAMMATORY activity. It is composed of HBQ COMPLEX (a patented complex consisting of the medicinal mushroom Hericium erinaceus, quercetin, and berberine) along with niacin and biotin.

BACKGROUND AND PURPOSE

Symptomatic uncomplicated diverticular disease (SUDD) is a recognized clinical condition characterized by abdominal pain and changes in bowel habits, attributed to diverticula but without macroscopic signs of diverticulitis. There is no consensus on the management of patients with SUDD. A retrospective observational study was conducted to evaluate the efficacy and safety of the nutraceutical ENTEROFLEGIN® for the treatment of patients with SUDD.

MATERIALS AND METHODS

Patients were treated with 2 tablets/day of ENTEROFLEGIN® for 10 days per month over a period of 6 months. The primary endpoint was the clinical remission rate, defined as the absence of symptoms. Secondary endpoints included the treatment's impact on symptom reduction, fecal calprotectin (FC) levels, and the prevention of acute diverticulitis.

Result

Data from 350 patients were retrospectively collected across 19 Italian Gastroenterology centers from January 1, 2020, to June 30, 2021 (183 males, 167 females, mean age 64 years). ENTEROFLEGIN® proved effective in inducing remission in 9.34% and 17.64% of patients at 3 and 6 months, respectively (p<0.001). A reduction in symptoms was observed in 92.3% and 85.3% of patients at 3 and 6 months, respectively (p<0.001). Only 1.71% of patients experienced recurrence or worsening of symptoms during follow-up. FC levels decreased from 181.3 μg/g at baseline to 100.2 μg/g (p<0.001) and 67.9 μg/g (p<0.001) at 3 and 6 months of follow-up, respectively. No adverse events were reported during follow-up. Finally, acute diverticulitis occurred in only 2% of patients during the follow-up period.

Conclusion

ENTEROFLEGIN® proved effective in achieving symptom remission in patients with SUDD.

This nutraceutical also proved to be safe. Further randomized, placebo-controlled clinical studies will be needed to confirm these preliminary findings.

Bibliography

Giovanni BRANDIMARTE, Giovanni V. FRAJESE, Stefano BARGIGGIA, Danilo CASTELLANI, Andrea COCCO, Raffaele COLUCCI, Enrica EVANGELISTA, Antonietta G. GRAVINA, Domenico NAPOLETANO, Elisabetta NARDI, Tammaro MAISTO, Antonino MORABITO, Giuseppe PIANESE, Antonio ROMANO, Rodolfo SACCO, Luca SEDIARI, Nicola SINNONA, Lorenza TIFI, Alessandro D’AVINO, Walter ELISEI, Antonio TURSI. Performance of a multicompounds nutraceutical formulation in patients with symptomatic uncomplicated diverticular disease. Minerva Gastroenterology 2022;68.

POST-MENOPAUSAL OSTEOPOROSIS: new guidelines from the Endocrine Society USA

/in /by

Come gestire l’osteoporosi in post-menopausa?

The Endocrine Society USA has published new guidelines. They emphasize increased screening, greater focus on prevention, and particular attention to pharmacological treatment. Which treatment is the most effective?

1. BISPHOSPHONATES: First-line treatment for postmenopausal osteoporosis.

2. Patients with MILD-MODERATE fracture risk, after 3–5 years, should consider the possibility of a "drug holiday," meaning a temporary suspension of therapy. The beneficial effects of bisphosphonates are evident even after discontinuation (RESIDUAL EFFECT). For other drug classes, the benefits are lost immediately after therapy is stopped!

3. MANDIBULAR OSTEONECROSIS: A rare event that occurs only with high doses of bisphosphonates (injectables used in cancer treatment). Currently, major U.S. dental associations have differing recommendations regarding BSF therapy: for instance, the ADA (American Dental Association) generally does not recommend discontinuing BSF treatment in conjunction with dental procedures, while the AAOMS (American Association of Oral and Maxillofacial Surgeons) suggests a drug holiday for a period of 2 months in patients who have been on BSF therapy for more than 4 years.  

Bibliography

Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1-28.